Amphetamine pretreatment induces a change in both D2-Receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats

Biol Psychiatry. 2004 Jun 15;55(12):1188-94. doi: 10.1016/j.biopsych.2004.02.019.

Abstract

Background: Measuring changes in dopamine (DA) levels in humans using radioligand-displacement studies and positron emission tomography (PET) has provided important empirical findings in disease and normal neurophysiology. These studies are based on the assumption that DA exerts a competitive inhibition on radioligand binding. To test this, we used PET and a Scatchard approach to investigate whether the decrease in [11C]raclopride binding following amphetamine results from competitive or noncompetitive interactions with DA.

Methods: Scatchard analyses of [11C]raclopride/PET data were used to quantify changes in apparent D2-receptor density (Bmax) and radioligand apparent affinity (K'D) at baseline and after amphetamine pretreatment (2 mg/kg; intravenous) in cats.

Results: Amphetamine induced a 46% decrease in [11C]raclopride binding in the striatum of five cats. Scatchard analyses revealed that this decrease in binding was due to a 28% decrease in Bmax and a concomitant 35% increase in K'D.

Conclusions: Competition with DA is an insufficient explanation for the decrease in [11C]raclopride binding observed after amphetamine. Noncompetitive interactions, likely representing D2-receptor internalization, also play an important role in this phenomenon. This finding may have important implications for the interpretation of amphetamine-raclopride PET studies in schizophrenia because dysregulation of the agonist-induced internalization of D2 receptors was recently suggested in this disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamine / administration & dosage
  • Amphetamine / pharmacology*
  • Animals
  • Binding, Competitive / drug effects
  • Blood Pressure / drug effects
  • Cats
  • Dopamine Antagonists* / pharmacokinetics
  • Dopamine Uptake Inhibitors / administration & dosage
  • Dopamine Uptake Inhibitors / pharmacology*
  • Functional Laterality / physiology
  • Injections, Intravenous
  • Neostriatum / drug effects
  • Neostriatum / metabolism
  • Raclopride* / pharmacokinetics
  • Radiopharmaceuticals / pharmacokinetics
  • Receptors, Dopamine D2 / drug effects*
  • Receptors, Dopamine D2 / metabolism*
  • Tomography, Emission-Computed

Substances

  • Dopamine Antagonists
  • Dopamine Uptake Inhibitors
  • Radiopharmaceuticals
  • Receptors, Dopamine D2
  • Raclopride
  • Amphetamine